Canigen Rabies
Active substance
ATC code
Species
Dogs and cats.
Indications
For the active immunisation against rabies to reduce clinical signs and mortality.
Onset of immunity: an adequate serological response (≥ 0.5 IU) has been demonstrated 2 to 3 weeks after vaccination.
Duration of immunity: 3 years.
Dose to be administered and administration route
Administer a dose of 1 ml irrespective of the size, species or breed of animal.
Intramuscular or subcutaneous use.
Sterile equipment should be used for administration. Avoid contamination of vaccine with traces of chemical sterilising agents. Do not use chemicals such as disinfectant or spirit to disinfect the skin prior to inoculation.
Primary course and booster vaccination in dogs and cats
Primary vaccination age* 12 weeks or older
Booster vaccination every 3 years
*The primary vaccination may be administered at an earlier age, but a second dose must then be administered at the age of 12 weeks. Minimum vaccination age in dogs and cats: 4 weeks.
Further information
Limited safety data for ferrets are available from monitoring post vaccination reactions. Ferrets can be vaccinated subcutaneously from 12 weeks of age. An adequate serological response (≥ 0.5 IU) has been demonstrated 1 month after vaccination.
Ferrets should receive a booster vaccination every 18 months.
Adverse reactions
Transient local reactions such as non-painful diffuse to firm swellings of approximately 1 cm in diameter may be observed for up to 3 weeks after subcutaneous vaccination.
A transient acute hypersensitivity reaction - with signs that may include, facial oedema, vomiting, pruritus or diarrhoea - may occur shortly after vaccination in very rare cases. Such reactions may evolve to a more severe condition (anaphylaxis), which may be life-threatening with additional signs like dyspnoea, collapse, ataxia, muscle tremor and convulsion. If such reactions occur appropriate treatment is recommended.
Clinical signs of immune-mediated haemolytic anaemia, immune-mediated thrombocytopenia or immune-mediated polyarthritis have been reported in very rare cases.
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
